Bavituximab
Based on 2 publication(s) in Google Scholar
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer.
For research use only. We do not sell to patients.
- Purity: 97.00%
- CAS No.: 648904-28-3
- Molecular Weight:145.336 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Bavituximab
More
Biological Activity
Human IgG1 kappa
Human
Phosphatidylserine
Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1)[1].
Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction[1].
Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2]
-
Dosage:100 μg/mouse (Bavituximab/β2GP1)
-
Administration:Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose)
-
Result:Traced phosphatidylserine exposure in vivo in mice with tumors.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 648904-28-3
-
Appearance Liquid
-
Molecular Weight 145.336 kDa
-
Color Colorless to light yellow
-
SMILES
[Bavituximab]
-
Synonyms
Anti-Human Phosphatidylserine Recombinant Antibody; PGN-401; CH3G4
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Cancer
CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8+ T cells. [Abstract]2026 May 15. PMID: 42141174 -
Cell Rep Med
Macrophage efferocytosis mediated by the TP63-RAC2 pathway promotes immunosuppressive remodeling in esophageal cancer. [Abstract]2025 Dec 18:102529. PMID: 41418775
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. [Content Brief]
[2]. Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bavituximab Related Classifications
HY-P99279 Related Classifications
Powered by Bioz